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of Noncalciﬁed Aortic Regurgitation*
John G. Webb, MD, Nay Htun, MDSEE PAGES 1831 AND 1842C urrent transcatheter heart valves (THVs)have been developed primarily for patientswith aortic stenosis. Most incorporate
metallic frames that rely on high radial force to an-
chor the implant within a stenotic and calciﬁed
native valve. However, aortic regurgitation (AR)
typically results from abnormalities of the aortic
cusps or root, often without associated calciﬁcation.
In patients with pure or predominant AR, it may not
be possible to securely anchor a THV, with the
potential for paravalvular regurgitation, malposi-
tion, or embolization.
Noncalciﬁc AR is much less common than calciﬁc
aortic stenosis; patients are typically younger and the
clinical course is more insidious. Moreover, patients
with pure AR often have an aortopathy, associated
with progressive dilation of the aortic root. This may
itself mandate aortic surgery and may contraindicate
THVs that depend on radial force for anchoring.
For these reasons, open surgical valve replacement
remains the treatment of choice for pure AR. How-
ever, in some patients with comorbidities, such as
severe left ventricular dysfunction or advanced age, a
less invasive approach may be appealing. We will
brieﬂy review the available THV options (Table 1).
ANCHORING IN THE ASCENDING AORTA
The CoreValve (Medtronic, Minneapolis, Minnesota)
has been used with some success in the absence of
valvular calciﬁcation. The very long frame anchors*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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the contents of this paper to disclose.not only in the aortic annulus, but also extends up to
the supracoronary aorta, improving stability. Several
registries document the feasibility in patients with
pure AR (1–3). In high surgical risk patients with
pure AR, the 30-day mortality rate has ranged from
9.3% to 23%, the stroke rate from 0% to 4.7%, and
the need for new pacemakers from 7.5% to 27.3%.
Residual AR that is greater than mild remained
in 20.9% to 23%. In the largest series to date (n ¼ 43),
a second THV was needed in 18.6% of patients, and
2.3% required conversion to open surgery (1). The
reported survival rate at 1 year ranged from 64% to
79%. Although these outcomes are less desirable than
reported with aortic stenosis, the CoreValve may
represent a useful alternative when surgery is not an
option (Figure 1).REPOSITIONABLE VALVES
The CoreValve’s successor, the Evolut R (Medtronic),
represents an attractive advance. This THV can be
partially, but not fully, deployed and yet be recap-
tured in its delivery catheter and repositioned or
removed if needed.Taking repositionability a step further, the inﬂat-
able Direct Flow THV (Direct Flow Medical Inc., Santa
Rosa, California) and the mechanically expanded
Lotus THV (Boston Scientiﬁc, Natick, Massachusetts)
can be fully deployed, assessed, and, if necessary,
repositioned or removed. In this issue of JACC: Car-
diovascular Interventions, Schofer et al. (4) report the
use of the Direct Flow THV in 11 high-risk patients with
pure AR. ARwas reduced tomild or less in all, although
in 1 patient, an unstable THV required surgical valve
replacement. At 30 days, the mortality rate was 9%
with no strokes (4). Experience with the Lotus THV in
pure AR is also favorable, but even more limited (5).
TABLE 1 Transcatheter Valves for Pure Aortic Regurgitation
CoreValve
(Medtronic)
Evolut R
(Medtronic)
Acurate
(Symetis SA)
Lotus
(Boston Scientiﬁc)
Direct Flow
(Direct Flow
Medical Inc.)
Engager
(Medtronic)
JenaValve
(JenaValve
Technology)
J-Valve
(JieCheng Medical
Technology)
Helio
(Edwards
Lifesciences)
Fixation
Annulus þ þ þ þ þ þ þ þ þ/
Aorta þ þ þ      
Leaﬂets      þ þ þ þþ
Self-positioning
Annulus   þ  þ    
Aorta þ þ þ      
Leaﬂets      þ þ þ þ
Repositionable þ/ þ  þþ þ/    
Dilating forces þ þ þ þ þ þ þ þ 
þ ¼ yes;  ¼ no.
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1851SELF-POSITIONING GEOMETRY
Some THVs incorporate self-seating geometry that
facilitates optimal positioning within the annulus.
The aortic and ventricular inﬂatable bladders of the
Direct Flow THV may assist in positioning and
anchoring. Similarly, the Acurate THV (Symetis SA,
Ecublens, Switzerland) has a narrower waist, which
may facilitate seating, along with a frame that ex-
tends into the aorta to facilitate coaxial alignment.
Wendt et al. (6) reported successful implantation in
8 patients with pure AR with a reduction in AR to
mild or less in all, with no deaths, major strokes, or
pacemakers.
ARCHES, FEELERS, AND GRASPERS
Other valves have taken self-positioning a step
further, incorporating design elements that use the
leaﬂets of the native valve to assist in THV posi-
tioning and ﬁxation.
The Engager (Medtronic) incorporates 3 nitinol
wire “arches” that, using a transapical approach,
are exposed in the aorta and withdrawn until they
contact the 3 native cusps; at this point, the self-
expanding THV is unsheathed and expanded. Expe-
rience with this device in pure AR is limited to
isolated reports (7).
JenaValve (JenaValve Technology, Munich, Germany)
incorporates 3 nitinol wire “feelers” that, using a trans-
apical approach, are similarly exposed in the aorta and
withdrawn until these contact the native cusps. As the
self-expanding frame is unsheathed, the native leaﬂets
are actively “clipped” between the feelers and the THV
frame, providing additional ﬁxation. Seiffert et al. (8) re-
ported their experience in 31 high-risk patients with pure
AR. Transcatheter aortic valve replacement was initially
successful in all but 1, in whom a second THV wasrequired. ARwas reduced inmild or less in all. At 30 days,
the mortality rate was 12.9%, with no patients experi-
encing strokes and new pacemakers implanted in 6.4%.
The survival rate at 6monthswas 80.7%. Schlingloff et al.
(9) reported their experiencewith 10 patientswith similar
high procedural success and low paravalvular AR rates,
but with a higher 30-day mortality rate of 20%.
J-Valve (JieCheng Medical Technology, Suzhou,
China), takes this approach further with mobile
nitinol wire leaﬂet “graspers” that may allow for ﬁne
positioning and active ﬁxation to the leaﬂets. In this
issue of JACC: Cardiovascular Interventions, Wei et al.
(10) report their experience in 6 high-risk patients. In
combination with another report by Zhu et al. (11),
this totals 13 patients with pure or predominant AR
reduced to mild or less in all, with no strokes, pace-
makers, or mortality at 30 days.
BALLOON-EXPANDABLE
Prototypic balloon-expandable tubular valves have
been avoided in the setting of pure AR. However, a
2-stage docking system has been effectively used by
our group and others in a small number of patients
(12). The Helio transcatheter aortic dock (Edwards
Lifesciences, Irvine, California) consists of a nitinol
frame placed in the aortic root behind the native
leaﬂets within which a balloon-expandable THV is
then deployed. The native leaﬂets are compressed
between the dock and THV, providing secure ﬁxa-
tion (and paravalvular sealing). A theoretical
advantage is the potential to resist progressive
annular dilation.
THE IDEAL VALVE?
Surgery remains the gold standard for pure AR,
although current THVs may offer an option for some
FIGURE 1 Transcatheter Heart Valves for Pure Aortic Regurgitation
(A) CoreValve Evolut R (Medtronic). (B) Acurate (Symetis SA). (C) Lotus (Boston Scientiﬁc). (D) Direct Flow (Direct Flow Medical Inc.). (E)
Engager (Medtronic). (F) JenaValve (JenaValve Technology). (G) J-Valve (JieCheng Medical Technology). (H) Helio dock (left) and SAPIEN
XT valve (right) (Edwards Lifesciences).
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1852patients. The association of AR with progressive
aortic dilation represents a particular concern as to
the durability of a conventional THV procedure.
Desirable features of future THV treatment for pure
AR might include the following: 1) minimally invasive
implantation; 2) facilitated active positioning; 3)
repositioning; 4) an effective seal; 5) a range of sizes
suitable for enlarged annuli; 6) durability; and 7)ﬁxation mechanisms that constrain, rather than
dilate, the aortic annulus. Options for AR continue to
improve, but compromise remains.
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